Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00608803 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors
A Phase 1 study of Advanced Cancer, sponsored by Alaunos Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT00608803: Completed Phase 1 study of Advanced Cancer, sponsored by Alaunos Therapeutics.
NCT00608803 is a Phase 1 study of Advanced Cancer that has completed, run by Alaunos Therapeutics. The registered enrollment target is 30 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00608803, a Phase 1 study of Advanced Cancer, has completed, sponsored by Alaunos Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study of safety of ZIO-201-T in combination with doxorubicin in the treatment of advanced cancer.
Conditions Studied
Interventions
- DRUG ZIO-201-T and doxorubicin
Study Locations (2)
California
- - Santa Monica
Texas
- - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
What the finished NCT00608803 record still lists
NCT00608803 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which ZIO-201-T and doxorubicin is the first listed.
NCT00608803 reports a single indexed study location in California, Texas.
Frequently Asked Questions
What is clinical trial NCT00608803 about?
NCT00608803 is a clinical study titled "Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors". The study of safety of ZIO-201-T in combination with doxorubicin in the treatment of advanced cancer.
What is the current status of trial NCT00608803?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2008-01. Estimated completion is 2009-01.
What conditions does trial NCT00608803 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT00608803?
The interventions under investigation include: ZIO-201-T and doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00608803?
This trial is sponsored by Alaunos Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00608803 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00608803's enrollment target sits among peer trials
30 97th of 122 higher than 20 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia